CARIPUL 0.5 MG
EPOPROSTENOL (EPOPROSTENOL SODIUM) : 0.5 MG · DIN 02397447 · JANSSEN INC
Health Canada status: MARKETED
What is CARIPUL?
CARIPUL 0.5 MG contains EPOPROSTENOL (EPOPROSTENOL SODIUM) : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02397447, held by JANSSEN INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 05-Nov-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARIPUL used for?
Long-term IV treatment of idiopathic/heritable pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease in NYHA Class III and IV patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02397447 |
|---|---|
| Brand name | CARIPUL |
| Generic / active ingredient | EPOPROSTENOL (EPOPROSTENOL SODIUM) : 0.5 MG |
| Manufacturer | JANSSEN INC |
| Strength | 0.5 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AC09 EPOPROSTENOL |
| AHFS class | 48:48.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Nov-2020 |
| Original market date | 2013-04-24 00:00:00 |
How is it administered?
Initiate at 2 ng/kg/min; increase by 2 ng/kg/min every 15+ mins until dose-limiting effects or tolerance limit. Administer via continuous IV infusion through a central venous catheter.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Do not expose reconstituted or diluted solutions to direct sunlight. (Specific temperature for powder not in snippet, but diluted solutions have specific stability at 2-8°C and 25°C).
How is it supplied?
10 mL vials, individually packaged in a carton. Available in 0.5 mg and 1.5 mg strengths.
Contraindications
Hypersensitivity to the drug or ingredients; congestive heart failure due to severe left ventricular systolic dysfunction; patients who develop pulmonary edema during dose initiation.
Warnings and precautions
Abrupt withdrawal may result in rebound pulmonary hypertension or death. Must be reconstituted only with Sterile Water or 0.9% NaCl. Avoid extravasation due to high pH.
What can be used instead?
Other Canadian products sharing ATC code B01AC09 EPOPROSTENOL. 4 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARIPUL | 1.5 MG | POWDER FOR SOLUTION | JANSSEN INC | MARKETED | DIN 02397455 |
| FLOLAN | 0.5 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02230845 |
| FLOLAN | 1.5 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02230848 |
| EPOPROSTENOL FOR INJECTION | 0.5 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02345706 |
| EPOPROSTENOL FOR INJECTION | 1.5 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02345714 |
Who else supplies EPOPROSTENOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EPOPROSTENOL appears in 14 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.